Drug Profile

KD 005

Alternative Names: KD-005; KN-035 - Nanjing KAEDI Biotech

Latest Information Update: 11 May 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nanjing KAEDI Biotech
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 May 2020 Discontinued - Phase-I/II for Cancer in China (Parenteral) (Nanjing KAEDI Biotech pipeline, May 2019)
25 Jul 2019 Phase-I/II clinical trials in Cancer in China (Parenteral) (Nanjing KAEDI Biotech July 2019)
21 Jun 2018 Preclinical trials in Cancer in China (Parenteral) (Nanjing KAEDI Biotech pipeline, June 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com